0
Post your comment
Last update: 11 March 2014
The regulatory body for approval of medicines in Nigeria is the National Agency for Food and Drugs Administration and Control (NAFDAC). The agency, through its Regulatory and Registration Directorate, is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in Nigeria.
Medicinal products cannot be manufactured, imported, exported, advertised, sold or distributed in Nigeria until they have been registered in accordance with the provisions of Decree 19 of 1993 as amended by Food, Drugs and Related Products (Registration) Decree No. 20 of 1999.
NAFDAC issued a guideline regarding the regulation of biosimilar products in December 2012. The NAFDAC guideline is an overarching guideline covering general considerations for biosimilar approval, such as selection of the reference drug, labelling requirements and fees.
NAFDAC has the following guidelines regarding biosimilars:
1. Overarching Guideline
This guideline covers all biosimilar products:
Guidelines for the registration of biosimilars in Nigeria
Date: December 2012
The guideline defines a biosimilar as a product that demonstrates similarity in terms of quality, safety and efficacy to a named reference biotherapeutic product licensed in Nigeria and/or by a stringent regulatory authority.
Editor’s comment
It should be noted that ‘biosimilars’ approved in Nigeria might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the EU. EMA regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.
Related article
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.
Source: NAFDAC
NPRA Malaysia trials new timelines for variation applications
Los nueve fármacos biológicos más vendidos en 2023
Nuevos hallazgos de semaglutida en el tratamiento de la hidradenitis supurativa
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
¡Regístrese hoy para recibir información semanal sobre los últimos avances en medicamentos genéricos y biosimilares!
Post your comment